Summit Therapeutics
SMMT
11 hedge funds and large institutions have $29.5M invested in Summit Therapeutics in 2015 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
0% more funds holding
Funds holding: 11 → 11 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% less capital invested
Capital invested by funds: $29.6M → $29.5M (-$89K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Axa
Paris,
France
|
+$998K |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$92.7K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$29.9K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$8.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$451K |
| 2 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$3.79K |
| 3 |
Citigroup
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LPU
1
Lansdowne Partners (UK)
London,
United Kingdom
| $9.68M | – | – | – |
|
|
2
Point72 Asset Management
Stamford,
Connecticut
| $9.57M | +$92.7K | +7,736 | +0.8% |
|
|
3
Axa
Paris,
France
| $3.92M | +$998K | +83,298 | +28% |
|
|
SFM
4
Sphera Funds Management
Tel Aviv,
Israel
| $2.14M | – | – | – |
|
5
First Eagle Investment Management
New York
| $1.82M | – | – | – |
|
|
GPCM
6
Granite Point Capital Management
Boston,
Massachusetts
| $1.33M | -$3.79K | -316 | -0.2% |
|
|
EAM
7
EverPoint Asset Management
Stamford,
Connecticut
| $1.04M | – | – | – |
|
|
8
Wells Fargo
San Francisco,
California
| $26K | +$29.9K | +2,500 | New |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $13K | +$14.7K | +1,228 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $9K | +$8.14K | +680 | +340% |
|
|
AIC
11
AWM Investment Company
New York
| – | -$451K | -42,693 | Closed |
|
|
12
Citigroup
New York
| – | -$1K | -53 | Closed |
|
13
Morgan Stanley
New York
| – | +$12 | +1 | +13% |
|
SMMT Hedge Fund Activity: Q3 2015 in Review
11 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Summit Therapeutics (SMMT) for Q3 2015, worth a combined $29.5M — down 0.3% from $29.6M a quarter earlier.
Fund positioning in SMMT was balanced in Q3 2015: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Axa, adding an estimated $998K. The largest seller was AWM Investment Company, exiting entirely with an estimated $451K sold.
- 11 institutional investors held Summit Therapeutics (SMMT) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $29.5M of Summit Therapeutics stock for Q3 2015, down 0.3% quarter-over-quarter.
- 2 funds opened new Summit Therapeutics positions in Q3 2015 and 2 closed out, a net change of 0 holders.
- The largest Summit Therapeutics buyer in Q3 2015 was Axa, an estimated $998K added.
- The largest Summit Therapeutics seller in Q3 2015 was AWM Investment Company, an estimated $451K sold.
Based on aggregated 13F filings for Q3 2015.